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Abstract:  
Diabetes resulting from heterozygosity for an inactivating mutation of the homeodomain 
transcription factor insulin promoter factor 1 (IPF-1) is due to a genetic defect of ß-cell function 
referred to as maturity-onset diabetes of the young 4. IPF-1 is required for the development of 
the pancreas and mediates glucose-responsive stimulation of insulin gene transcription. To 
quantitate islet cell responses in a family harboring a Pro63fsdelC mutation in IPF-1, we 
performed a five-step (1-h intervals) hyperglycemic clamp on seven heterozygous members 
(NM) and eight normal genotype members (NN). During the last 30 min of the fifth glucose step, 
glucagon-like peptide 1 (GLP-1) was also infused (1.5 pmol • kg
-1
 • min
-1
). Fasting plasma 
glucose levels were greater in the NM group than in the NN group (9.2 vs. 5.9 mmol/l, 
respectively; P < 0.05). Fasting insulin levels were similar in both groups (72 vs. 105 pmol/l for 
NN vs. NM, respectively). First-phase insulin and C-peptide responses were absent in 
individuals in the NM group, who had markedly attenuated insulin responses to glucose alone 
compared with the NN group. At a glucose level of 16.8 mmol/l above fasting level, GLP-1 aug-
mented insulin secretion equivalently (fold increase) in both groups, but the insulin and C-
peptide responses to GLP-1 were sevenfold less in the NM subjects than in the NN subjects. In 
both groups, glucagon levels fell during each glycemic plateau, and a further reduction occurred 
during the GLP-1 infusion. Sigmoidal dose-response curves of glucose clearance versus insulin 
levels during the hyperglycemic clamp in the two small groups showed both a left shift and a 
lower maximal response in the NM group compared with the NN group, which is consistent with 
an increased insulin sensitivity in the NM subjects. A sharp decline occurred in the dose- 
response curve for suppression of nonesterified fatty acids versus insulin levels in the NM group. 
We conclude that the Pro63fsdelC IPF-1 mutation is associated with a severe impairment of ß-
cell sensitivity to glucose and an apparent increase in peripheral tissue sensitivity to insulin and 
is a genetically determined cause of ß-cell dysfunction. Diabetes 49:1856–1864, 2000 
 
Article: 
Type 2 diabetes is a highly prevalent and heterogeneous disorder of glucose homeostasis 
characterized by an imbalance between insulin synthesis and secretion by the endocrine 
pancreatic ß-cells and peripheral tissue sensitivity to insulin. Diabetes has long been recognized 
as a genetic disorder with complex modes of inheritance. Recent advances reveal the genetic 
basis for a monogenic type of diabetes referred to as maturity-onset diabetes of the young 
(MODY), which is characterized by diagnosis at <25 years of age, autosomal dominant 
inheritance, and lack of a requirement for insulin therapy for at least 5 years after initial 
diagnosis (1). To date, five MODY genes have been identified, four of which encode endocrine 
pancreatic transcription factors (2–5) and one that encodes the pancreatic and hepatic glycolytic 
enzyme glucokinase (6,7). 
 
Insulin promoter factor 1 (IPF-1) (also known as STF-1, IDF- 1, IDX- 1, and PDX-1) is a 
homeodomain transcription factor that is absolutely required for the development of the pancreas 
(8,9) and also mediates glucose-responsive stimulation of insulin gene transcription (10–15). 
IPF-1 is also implicated in the transcriptional regulation of other key ß-cell specific genes, 
including GLUT2 (16), islet amyloid polypeptide (17,18), and glucokinase (19). Earlier, we 
described a child born with pancreatic agenesis who is homozygous for an inactivating cytosine 
deletion mutation in the protein coding sequence of IPF-1 (Pro63fsdelC) (8). Subsequently, we 
showed that the IPF-1 mutation is linked to autosomal dominant early-onset type 2 diabetes in 
heterozygous carriers of the mutant allele within both branches of the extended family of the 
proband (Fig. 1) (4). Three members of this pedigree (II-4, IV-7, and IV-8) satisfy the strictest 
criteria for the diagnosis of MODY4, and two additional subjects heterozygous for the 
Pro63fsdelC mutation developed either diabetes or glucose intolerance before 30 years of age 
(IV-6 and IV-9), thus establishing IPF-1 as the MODY4 gene (4). 
 
The relevance of these advances in genetic defects of the ß-cell (MODY) to the genetics and 
pathophysiology of type 2 diabetes is demonstrated by the identification of mutations in these 
genes in subjects with more common late- onset type 2 diabetes (20,21). Seven new 
heterozygous IPF1 mutations have been discovered in 10 French pedigrees, 4 British pedigrees, 
and 1 Japanese pedigree, all with late- onset type 2 diabetes. An examples of digenic inheritance 
has been reported in a family with late-onset type 2 diabetes in which the severity of the diabetic 
phenotype appears to be related to cosegregation of two distinct mutations in two different 
pancreatic transcription factor genes, one of which is IPF-1 (22). 
 
An initial clinical evaluation of MODY subjects revealed a defect in glucose-induced insulin 
secretion, but the nature of the deficit varies among the MODY subtypes. The aim of this study 
was to define the pathophysiology of mono- genetic diabetes resulting from the Pro63fsdelC 
IPF-1 mutation (MODY4) and to characterize the pattern of the ß-cell insulin secretory response 
across a wide range of hyperglycemia. Understanding the pathophysiology of diabetes resulting 
from IPF-1 mutations may have broad relevance to the diagnosis and treatment of a subset of 
late-onset type 2 diabetes. 
 
RESEARCH DESIGN AND METHODS 
Subjects. A total of 15 members (7 heterozygous for the Pro63fsdelC mutation in IPF-1 [NM] 
and 8 normal genotypes [NN]) of both branches of the MODY4 family (4) volunteered for 
participation in this study (Fig. 1). The clinical characteristics of the volunteers are described in 
Table 1. The Human Investigation Committee of the University of Virginia approved all methods 
and procedures. All volunteers gave their written informed consent. 
 
Body composition and pancreas size. Total body fat mass, lean tissue mass, and bone mineral 
content were determined by dual-energy X-ray absorptiometry (DXA). DXA scans were 
performed in the pencil beam mode using the Hologic QDR 2000 (Waltham, MA) bone  
 
  
densitometer. All scans were analyzed by an expert technician using the Hologic Enhanced 
Whole- Body Software Version 7.2. 
 
Computed tomography scans were performed with a Picker PQ 5000 (Cleveland, OH) and were 
analyzed with a tissue quantification analysis package on the Picker Voxel Q 3D imaging station. 
Subjects were examined in a supine position with their arms stretched above their heads. An 
abdominal scan at the level of the L4 to L5 intervertebral disc space was performed with no 
angulation using a lateral pilot for location, and abdominal visceral fat (AVF) and abdominal 
subcutaneous fat (ASF) cross-sectional areas were calculated as previously described (23). Fat 
content and muscle area of the thigh were assessed from a single slice taken at midpoint between 
the greater trochanter and the top of the patella (with the subject standing). To estimate the mass 
of the pancreas, a spiral series (pitch 1.5) of abdominal scans was taken to include the whole 
pancreas. The pancreatic area determined for each slice was multiplied by the slice interval 
thickness to provide a pancreatic tissue volume for each slice. The volume of pancreatic tissue 
for each slice was summed from all images.  
 
Five-step hyperglycemic clamp. All subjects were asked to consume a weight-maintaining diet 
without carbohydrate restriction and to maintain their usual level of physical activity for 3 days 
before testing. All hypoglycemic medications were withheld for 18 h before the start of the 
clamp. Each volunteer was admitted to the General Clinical Research Center the evening before 
the test. All clamps were performed after an overnight fast, and testing began by 0730 as 
described previously (24). After determination of the stable fasting state, at time 0, a five-step 
hyperglycemic clamp was initiated. Each clamp step lasted 1 h. Initially, the fasting plasma 
glucose levels were increased by 5.6 mmol/l (100 mg/dl) for 1 h followed by 2.8 mmol/l (50 
mg/dl) for each of the subsequent 4 h. During the last 30 min of the fifth glucose step, glucagon-
like peptide 1 (GLP-1) (7-36 amide) was infused in a primed (10 min) constant (20 min, 1.5 
pmol • kg
-1
 • min
-1
) manner as described previously (25). Synthesized GLP-1 (Boston Molecules, 
Woburn, MA) has a peptide content of 75%. This preparation was >99% pure and displayed a 
single peak on high- performance liquid chromatography. The peptide was lyophilized in vials 
under sterile conditions for single use and was certified to be both sterile and pyrogen free; the 
net peptide content was used for dose calculations. At 300 min, glucose and GLP-1 infusions 
were terminated, and all parameters were followed for the next 30 min. During the clamp, 
samples for plasma glucose, insulin, C-peptide, glucagon, GLP-1, pancreatic polypeptide (PP), 
and nonesterified fatty acids (NEFAs) were obtained as follows: glucose, for each step at 2-min 
intervals for the first 10 min and at 5-min intervals thereafter; insulin and C-peptide, for each 
step at 2-min intervals for the first 10 min and at 10-min intervals thereafter until 270 min 
followed by 5-min samples until 330 min; GLP1, every 30 min until 240 min and at 5-min 
intervals until 330 min; glucagon, PP, and NEFA, at 10-min intervals throughout the study. 
 
Analytical techniques. Blood samples were collected in heparinized syringes. Plasma glucose 
was immediately assayed by the glucose oxidase method (Beckman Glucose Analyzer II;  
Fullerton, CA). The remaining blood samples were placed in prechilled test tubes containing 
kallikrein-trypsin inhibitor (Trasylol; Bayer, Kaukakee, IL), EDTA as previously described (25), 
 
 
and diprotin A (Bachem, Torrance, CA) (0.1 µmol/ml blood). Plasma samples were aliquoted 
and frozen (–80°C) for subsequent analysis. All determinations were performed in duplicate 
except for NEFA. Plasma insulin, C-peptide, GLP-1, glucagon, and PP were determined as 
previously described (25–27). The PP antibody was obtained from Linco Research (St. Louis, 
MO). NEFA was measured by an enzymatic colorimetic method (Wako Chemicals, Richmond, 
VA).  
 
Statistical methods. Glucose utilization was calculated at 30-min intervals from 0 to 300 min as 
previously described (24). Metabolic clearance rate (MCR) of glucose (ml • kg
-1
 • min
-1
) (the 
volume of plasma from which glucose is completely and irreversibly removed per unit time) was 
calculated as glucose utilization divided by the concentration of glucose for the specific time. 
The trapezoidal rule was used to calculate the integrated responses over 30-min intervals. The 
integrated responses were divided by the time interval, which resulted in mean concentrations or 
values. 
 
All data were analyzed using SAS Version 6.12 software (Cary, NC). Mixed- model analysis 
from a repeated-measures design was used to analyze hormone and metabolite responses. The 
dose-response relationships of the mean 30-min plasma insulin concentrations with MCR and the 
percentage of suppression of NEFA was modeled using a four-parameter logistical equation that 
characterizes a sigmoidal curve (28). The group half-maximal effective concentration (ED50) was 
estimated from the sigmoidal fit of the data. Except where otherwise stated, data are means ± SE. 
RESULTS 
The two groups of volunteer subjects were similar regarding age, weight, and BMI (Table 1). 
However, the NM group was 10 years older (P = 0.30), and six of the seven subjects in that 
group had diabetes. The ratio of men:women in the NM and NN groups was 5:2 and 2:6, 
respectively. Despite this difference, total percentages of fat (P < 0.06), AVF (121.1± 20.4 vs. 
130.8 ± 27.2 cm
2
, respectively; P = 0.78), ASF (287.8± 37.3 vs. 447.5 ± 100.8 cm
2
, respectively; 
P = 0.14), and thigh fat (95.2 ± 19.8 vs. 162.3 ± 38.6 cm
2
, respectively; P = 0.12) were not 
different; thigh muscle area was also similar (134.2 ± 11.8 vs. 109.7 ± 9.5 cm
2
, respectively; P = 
0.16). Pancreas volume in the NM group was smaller (62.2 ± 7.9 vs. 75.9 ± 9.2 cm
3
, 
respectively; P = 0.28). 
 
Fasting plasma glucose levels in the NM and NN groups were 9.2 ± 1.6 and 5.9 ± 0.4 mmol/l, 
respectively. During each step of the clamp, plasma glucose was maintained at a stable level in 
each volunteer. The mean increase of plasma glucose plateau for each step of the clamp was 5.4 
± 0.05, 8.6 ± 0.20, 10.8 ± 0.27, 14.1 ± 0.33, and 15.9 ± 0.28 mmol/l above fasting level in the 
NM group. The corresponding levels for the NN group were 5.5 ± 0.21, 8.3 ± 0.31, 10.7 ± 0.28, 
13.7 ± 0.24, and 16.6 ± 0.35 mmol/l (Fig. 2). Despite equivalent increases in the plasma glucose 
levels in the two groups, average glucose infusion rates necessary to maintain stable 
hyperglycemia during the last 30 min of each step were 126, 260, 260, 215, and 197% higher in 
the NN group compared with the NM group (P < 0.01 for steps 2–5) (Fig. 2). 
 
Fasting plasma insulin levels in the NM and NN groups were 72 ± 7 and 105 ± 16 pmol/l, 
respectively. In response to the square wave of hyperglycemia, first-phase insulin response was 
absent in the NM group and was clearly evident in the NN group (Fig. 3). The peak levels at 4 
min were 84 ± 12 and 317 ± 44 pmol/l in the NM and NN groups, respectively (P < 0.01). After 
the initial step of the clamp, a first-phase insulin response was not observed in the subsequent 
four steps in either group. In the NM group, second- phase insulin response changed little, but in 
the NN group, it increased progressively at each step of the clamp (Fig. 3). 
 
The 30- to 60-min and the 240- to 270-min plasma insulin levels of the NM group averaged 122 
± 31 and 596 ± 238 pmol/l, respectively. The corresponding plasma insulin levels in the NN 
group were 487 ± 87 and 4,098 ± 908 pmol/l, respectively. During the 270- to 300-min period 
when GLP-1 was also infused, insulin responses in the NM group were sevenfold less than in the 
NN group (1,481 ± 691 and 9,998 ± 1,703 pmol/l, respectively; P < 0.01). However, the fold 
increase over glucose alone at the 240- to 270-min period was the same in both groups (~2.5-
fold). 
 
The time course of the C-peptide response to glucose and GLP-1 was similar to the time course 
of the insulin response (Fig. 3). The ratios of fasting plasma insulin to fasting C-peptide levels 
for the NM and NN groups were 0.14 and 0.14, respectively. The ratios of insulin to C-peptide 
for the last 30 min of each of the first four steps in the NM group were 0. 12, 0.14, 0.12, and 
0.14, respectively. The 240- to 270-min and the 270- to 300-min ratios were 0.15 and 0.20, 
respectively. The corresponding ratios for the NN group were 0.20, 0.25, 0.32, 0.38, 0.43, and 
0.60, respectively (all P  0.005). 
 
 
 
 
 
The lower limit of GLP-1 detection in our laboratory is 5 pmol/l. Endogenous plasma GLP-1 
levels in both groups during the fasting state as well as during the first 270 min of the glucose 
infusion period were either below the level of detection or slightly >5 pmol/l. When a level was 
<3 pmol/l, the value 3 pmol/l was assigned to that sample. Fasting GLP-1 levels in the NM and 
NN groups were 3.3 ± 0.2 and 3.5 ± 0.2 pmol/l, respectively. The 240- to 270-min levels were 
3.4 ± 0.3 and 3.5 ± 0.3 pmol/l, respectively. With the infusion of GLP-1 plasma, GLP-1 levels 
rose rapidly in both groups, and the 270- to 300-min concentrations were similar and averaged 
155 ± 36 and 195 ± 27 pmol/l in the NM and NN groups, respectively (Fig. 3). 
 
The fasting plasma PP levels in the NM and NN groups were similar and averaged 36 ± 9 and 51 
± 23 pmol/l, respectively. Plasma PP levels did not change significantly during either the glucose 
infusion alone or when GLP-1 was also infused (Fig. 4). 
 
Fasting plasma glucagon levels in the NM and the NN groups averaged 17.2 ± 1.4 and 14.4 ± 2.0 
pmol/l, respectively (Fig. 4). With the start of the glucose infusion, plasma glucagon levels began 
to fall in both groups. The 240- to 270-min levels averaged 10.6 ± 1.3 and 7.1 ± 1.4 pmol/l in the 
NM and NN groups, respectively. The suppression is significant in both groups compared with 
the fasting level (P  0.01) but not between the two groups (P = 0.09). During the GLP-1 
infusion period, despite vast differences in insulin response between the two groups, glucagon 
levels fell to 9.4 ± 1.0 and 6.7 ± 1.2 pmol/l in the NM and NN groups, respectively; these were 
not significantly different from each other or from the 240- to 270-min levels. However, the 
decrease in the glucagon levels during the entire clamp study was statistically significant (P < 
0.0001). No statistically significant difference was evident in the pattern of decrease between the 
two groups (P = 0.87). 
 
Fasting NEFA levels in the NM and the NN groups differed and averaged 0.74 ± 0.08 and 0.52 ± 
0.08 mmol/l, respectively (P < 0.04). After the start of glucose infusion, NEFA levels began to 
decrease in both groups and reached a plateau by 120 min (Fig. 4). The 240- to 270-min levels 
were 0.26 ± 0.06 and 0.26 ± 0.08 mmol/l in the NM and the NN groups, respectively. Despite 
having a higher fasting NEFA level, the NM group suppressed to the same level as the NN 
group. During the GLP-1 infusion period, NEFA levels were 0.20 ± 0.05 and 0.24 ± 0.8 mmol/l 
in the NM and the NN groups, respectively. These levels were not different from each other or 
from the previous 30-min interval. The decrease in NEFA levels during the entire clamp was 
statistically significant (P < 0.0001), and a significant difference was evident in the pattern of 
decrease between the two groups (P < 0.04). 
 
We also examined insulin sensitivity regarding both glucose uptake (Fig. 5) and suppression of 
NEFA (Fig. 6). Because fasting plasma glucose levels were significantly higher in the NM 
group, we calculated the MCR of glucose. A significant dose-response relationship was evident 
between glucose clearance and plasma insulin level. The NM group’s curve for glucose 
clearance was shifted to the left and had a lower maximal response compared with the NN group. 
 
The ED50 values for insulin in the NM and NN groups were 348 and 874 pmol/l, respectively (58 
and 146 µU/ml, respectively; P = 0.003). Similarly, the pattern of decrease in NEFA between the 
two groups was different. A steeper decline in NEFA is evident in the NM group compared with 
the NN group. The ED50 values for insulin in the NM and NN groups were 142 and 384 pmol/l, 
respectively (24 and 64 µU/ml, respectively; P = 0.004). Thus, a maximal suppression in NEFA 
is achieved at a lower insulin level in the NM group. In stepwise regression analyses where the 
independent variables were sex, genotype (NM, NN), age, BMI, fasting glucose, AVF, ASF, 
percentage of body fat, thigh muscle area, and pancreas volume, only the presence or absence of 
the mutation was related to the MCR of glucose, with the dependent variable accounting for 44% 
of the variance (P = 0.007). 
 
DISCUSSION 
The main focus of this study describes insulin release in response to changes in plasma glucose 
levels across a wide range of hyperglycemia in members of a family who have inherited an 
inactivating mutation within one of two alleles of the IPF-1 gene. A severe impairment of insulin 
release is demonstrated compared with members of the same family who do not harbor the 
mutation. The impairment appears to be specific for glucose-stimulated insulin release because 
no differences are apparent in the fold increase for GLP-1–stimulated insulin release (240- to 
270-min interval/270- to 300-min interval). Furthermore, the impairment also appears to be ß-
cell specific because no differences in α-cell or PP cell responses were seen. However, specific 
provocative tests such as an arginine stimulation test and a meal tolerance test are necessary to 
establish the lack of differences in α- and PP cell sensitivities. 
 
In type 2 diabetic volunteers and in contrast with nondiabetic volunteers, a first-phase insulin 
response does not occur during a hyperglycemic clamp at a glucose level of 5.6 mmol/l above 
fasting level (29). First-phase insulin response was also absent in each volunteer of the NM 
group during the first clamp step (5.6 mmol/l above fasting level). This circumstance was 
observed even in those individuals who were just diagnosed as having elevated fasting glucose 
levels consistent with the diagnosis of diabetes at the time of the study. The first- phase insulin 
responses were also absent in both groups during each of the subsequent four steps. Although, 
during the fifth step of the glucose clamp, plasma glucose levels were substantially elevated, the 
incremental step from the fourth to the fifth step was rather small (from 13.9 to 16.7 mmol/l). 
Thus, to obtain a second first-phase response during a stepped hyperglycemic clamp, a larger 
incremental increase in plasma glucose may be necessary than is required for the increment from 
a fasting plasma glucose level. 
 
Recently, a two-step hyperglycemic clamp (each step 2.5 mmol/l above fasting level) was 
reported in five members of a MODY3 family (hepatocyte nuclear factor-1a gene mutation) and 
six nondiabetic nonrelated control volunteers (30). Similar to our study, first-phase insulin 
responses did not occur during either of the two steps in the MODY3 volunteers, and second-
phase insulin responses were markedly attenuated during the first step. In the six nondiabetic 
volunteers, first- and second-phase insulin responses during the first step of the clamp were 
normal. During the second step, first- phase insulin response was absent, but an increase was evi-
dent in the second phase; those findings contrast with the findings of MODY3 volunteers in 
whom very little increase occurred in insulin secretion. Markedly attenuated insulin secretion 
rates (ISRs) (deconvolution of plasma C-peptide) in response to an increase in plasma glucose 
with a relatively constant slope (ramp) have also been reported in affected diabetic members of 
MODY3 families from France, Michigan, and New York pedigrees (31). Insulin responses and 
ISRs were also reduced in nondiabetic affected members compared with nondiabetic nonrelated 
control volunteers. 
 
Diminished insulin responses (both phases) during hyperglycemic clamps (5.6 mmol/l above 
fasting) have been reported for both diabetic and nondiabetic members of a MODY1 pedigree 
compared with nonrelated control volunteers (32). Furthermore, diminished insulin and glucagon 
responses occur in response to an arginine infusion both before and during the clamp in the 
diabetic and nondiabetic MODY1 groups. Diminished ISR in response to ramp increases in 
plasma glucose levels have also been reported in affected members of the MODY1 Michigan 
family (R.W.) compared with nonmutated members (33). The reduction in ISR became more 
evident as plasma glucose levels increased. Because high blood glucose per se may cause a 
decrease in ISR, we separately analyzed subject II-4-M, who had a fasting glucose of 4.6 mmol/l. 
We found that he also had a severely deficient first-phase insulin response as well as a defective 
second-phase insulin response. Therefore, we believe that IPF-1 mutations cause a primary 
defect in insulin secretion. 
 
In contrast with MODY1, MODY3, and MODY4, in which first-phase insulin responses similar 
to type 2 diabetes are absent, these responses are present in MODY2-affected members with the 
glucokinase mutation (34,35). However, 
ISRs in response to ramp are lower than in control volunteers (35). Again, the reduction in 
insulin response, similar to MODY1 and MODY3, became more evident as plasma glucose 
levels increased to >9 mmol/l. Phenotypic evaluation of insulin response in MODY5 has not 
been reported (5). Thus, taken together, all types of MODY-affected members who have been 
examined up to this point display a marked reduction in insulin responses to glucose. However, 
MODY4-affected members do not have an impairment in GLP-1–stimulated insulin response, 
and this may prove to be a new and effective agent for controlling their glucose homeostasis. 
 
We also examined peripheral tissue sensitivity to endogenously released insulin. We observed 
that the tissue sensitivity in the NM group was significantly higher compared with the NN group. 
However, we point out that the ranges of endogenously released insulin are different between the 
two small groups and that we used MCR as a measure of peripheral tissue sensitivity. 
Additionally, this apparent increase in peripheral tissue sensitivity to insulin was not determined 
with a hyperinsulinimic-euglycemic clamp in which plasma insulin levels are the same in each 
volunteer. In another study, glucose uptake in diabetic MODY3 volunteers during a euglycemic 
clamp was slightly higher than in nondiabetic MODY3 volunteers (55 vs. 43 µmol • kg
-1
 fat-free 
mass • min
-1
); the difference was not significant (36). Thus, the peripheral tissue sensitivity to 
insulin of MODY3 individuals is not increased. However, MODY2 individuals appear to have a 
diminished peripheral tissue sensitivity to insulin accompanied by less reduction in hepatic 
glucose output during hyperinsulinemia (37). The improved peripheral tissue sensitivity to 
insulin in our study is not limited to glucose. We also observed improved fatty acid suppression 
in the NM group. The female:male ratio in the NM group (2:5) was opposite that of the NN 
group (6:2), and the NM group had a lower BMI and percentage of body fat. However, in 
stepwise regression analysis, only the presence or absence of the mutation accounted for the 
improvement in glucose homeostasis. Thus, this study provides preliminary evidence that a 
mechanism for maintaining fuel homeostasis in MODY4 individuals is an increased peripheral 
tissue sensitivity to insulin for the uptake of both glucose and fatty acids. Whether this enhanced 
sensitivity is also exhibited regarding protein and hepatic glucose output remains to be examined. 
 
In conclusion, we demonstrate that, despite a markedly diminished ß-cell response to 
hyperglycemia in MODY 4 individuals, the responses to glucose in the islet α-cells (glucagon) 
and PP cells are unaffected. Furthermore, the ß-cell response to the insulinotropic hormone GLP-
1 remains intact. An improved peripheral tissue sensitivity probably compensates at least in part 
for the diminished insulin secretion. 
 
Since submitting our article for consideration, two articles have been published (20,21). Both of 
those showed that defective mutations in IPF-1 led to type 2 diabetes in heterozygotes. Hani et 
al. (20) showed that carriers of the D76N IPF-1 mutation with perfectly normal glucose tolerance 
had significant and dramatic decreases in insulin response to an oral glucose tolerance test both 
at 30 min and throughout the rest of the test. Therefore, we believe that this indicates that IPF-I 
mutations lead to a primary defect in insulin secretion. 
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